Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate-severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
Keywords: JAK inhibitors; atopic dermatitis; dermatology; eczema; tofacitinib.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.